Rebound of medication abortion in Texas following updated mifepristone label

Contraception. 2019 May;99(5):278-280. doi: 10.1016/j.contraception.2019.01.001. Epub 2019 Jan 23.

Abstract

Background: In 2013, Texas House Bill 2 (HB 2) placed restrictions on the use of medication abortion, which later were nullified with the 2016 FDA-approved mifepristone label.

Methods: Using data collected directly from Texas abortion facilities, we evaluated changes in the provision and use of medication abortion during three 6-month time periods corresponding to the policy changes: before HB 2, after HB 2 and after the label change.

Results: Medication abortion constituted 28% of all abortions before HB 2, 10% after implementation of the restrictions and 33% after the label change.

Conclusions: Use of medication abortion in Texas rebounded after the FDA label change.

Keywords: Abortion restrictions; House Bill 2; Medication abortion; Mifepristone; Texas.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abortion, Induced / legislation & jurisprudence*
  • Abortion, Induced / trends*
  • Ambulatory Care Facilities
  • Drug Labeling*
  • Female
  • Humans
  • Legislation, Drug*
  • Mifepristone / therapeutic use*
  • Pregnancy
  • Texas
  • United States
  • United States Food and Drug Administration

Substances

  • Mifepristone